Clinical Trial Update: Fulvestrant With or Without AZD6244 in Treating Patients With Advanced Breast Cancer That Progressed After Aromatase Inhibitor Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating fulvestrant with or without AZD6244 in advanced breast cancer after aromatase inhibitor progression has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AZD6244 (selumetinib)
• Fulvestrant (fulvestrant)

Snippet

Sponsor: Swiss Cancer Institute | Conditions: Breast Cancer | Phase 2 | Status: COMPLETED